179 related articles for article (PubMed ID: 17071479)
1. CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
Savaşan S; Buck S; Raimondi SC; Becton DL; Weinstein H; Chang M; Ravindranath Y
Leuk Lymphoma; 2006 Oct; 47(10):2076-83. PubMed ID: 17071479
[TBL] [Abstract][Full Text] [Related]
2. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
4. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
[TBL] [Abstract][Full Text] [Related]
5. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
6. CD36 - a marker for drug sensitive acute megakaryoblastic leukemia.
Gurbuxani S
Leuk Lymphoma; 2006 Oct; 47(10):2004-5. PubMed ID: 17071466
[No Abstract] [Full Text] [Related]
7. Molecular lesions in childhood and adult acute megakaryoblastic leukaemia.
Hama A; Muramatsu H; Makishima H; Sugimoto Y; Szpurka H; Jasek M; O'Keefe C; Takahashi Y; Sakaguchi H; Doisaki S; Shimada A; Watanabe N; Kato K; Kiyoi H; Naoe T; Kojima S; Maciejewski JP
Br J Haematol; 2012 Feb; 156(3):316-25. PubMed ID: 22122069
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
9. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia.
Qi H; Mao Y; Cao Q; Sun X; Kuai W; Song J; Ma L; Hong Z; Hu J; Zhou G
Med Sci Monit; 2020 Jun; 26():e922662. PubMed ID: 32532951
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural and ultracytochemical differences between megakaryoblastic leukemia in children and adults. Analysis of 49 patients.
Eguchi M; Ozawa T; Sakakibara H; Sugita K; Iwama Y; Furukawa T
Cancer; 1992 Jul; 70(2):451-8. PubMed ID: 1319816
[TBL] [Abstract][Full Text] [Related]
12. Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia").
Slørdahl SH; Smeland EB; Holte H; Grønn M; Lie SO; Seip M
Med Pediatr Oncol; 1993; 21(4):254-8. PubMed ID: 8469219
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia With Unusual Immunophenotype.
Koulmane Laxminarayana SL; Kohli S; Agrohi J; Belurkar S
Cureus; 2023 Mar; 15(3):e35965. PubMed ID: 36911590
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
[TBL] [Abstract][Full Text] [Related]
15. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
[TBL] [Abstract][Full Text] [Related]
16. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics.
Panda D; Chatterjee G; Sardana R; Khanka T; Ghogale S; Deshpande N; Badrinath Y; Shetty D; Narula G; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2021 Mar; 100(2):206-217. PubMed ID: 32865882
[TBL] [Abstract][Full Text] [Related]
17. Acute Megakaryoblastic Leukemia Associated with Trisomy 21 Demonstrates a Distinct Immunophenotype.
Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang H; Chen W
Cytometry B Clin Cytom; 2014 Oct; ():. PubMed ID: 25302938
[TBL] [Abstract][Full Text] [Related]
18. Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.
Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Hori H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 2001 Dec; 74(4):428-36. PubMed ID: 11794699
[TBL] [Abstract][Full Text] [Related]
19. Acute megakaryoblastic leukemia in Down syndrome.
Hitzler JK
Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
[TBL] [Abstract][Full Text] [Related]
20. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome.
Holt SE; Brown EJ; Zipursky A
J Pediatr Hematol Oncol; 2002 Jan; 24(1):14-7. PubMed ID: 11902731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
